Home > Control of 1-benzylpiperazine (BZP) and related compounds.

Advisory Council on the Misuse of Drugs. [Home Office UK] (2009) Control of 1-benzylpiperazine (BZP) and related compounds. London: Home Office. 19 p.

[img]
Preview
PDF (1-benzylpiperazine (BZP) report) - Published Version
98kB

BZP is a recreational stimulant, which gained popularity in some countries in the early 2000’s as a legal alternative to amphetamine, methylamphetamine, and 3, 4-methylenedioxy-N-methylamphetamine (MDMA - ecstasy). BZP is a central nervous system (CNS) stimulant with about 10% of the potency of d-amphetamine.

The UK ACMD considers that the harms and misuse of BZP and substituted piperazines (identified in Annex 4) are commensurate with Class C, under Schedule 2, part III, of the Misuse of Drugs Act (1971); and should be scheduled under Schedule I of the Misuse of Drugs Regulations (2001) (having no recognised medicinal use).


Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance, CNS stimulants
Intervention Type:AOD disorder harm reduction
Source:Home Office UK
Date:2009
Pages:19 p.
Publisher:Home Office
Corporate Creators:Advisory Council on the Misuse of Drugs
Place of Publication:London
EndNote:View
Accession Number:HRB (Electronic Only)
Related URLs:
Subjects:MM-MO Crime and law > Substance use laws > Drug laws
B Substances > CNS stimulants
L Social psychology and related concepts > Legal availability or accessibility
B Substances > New (novel) psychoactive substances
J Health care, prevention and rehabilitation > Health care administration > Health care quality control
VA Geographic area > Europe > United Kingdom
B Substances > CNS stimulants > BZP (Benzylpiperazine) (other piperazines)
MP-MR Policy, planning, economics, work and social services > Policy > Policy on substance use

Repository Staff Only: item control page